tiprankstipranks
Verrica Pharmaceuticals (DE:1NE)
FRANKFURT:1NE
Holding DE:1NE?
Track your performance easily

Verrica Pharmaceuticals (1NE) Income Statement

2 Followers

Verrica Pharmaceuticals Income Statement

Last quarter (Q3 2024), Verrica Pharmaceuticals's total revenue was $-1.78M, a decrease of -161.06% from the same quarter last year. In Q3, Verrica Pharmaceuticals's net income was $-20.05M. See Verrica Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 9.21M$ 5.12M$ 9.03M$ 12.00M--
Cost of Revenue
$ 2.07M$ 746.00K$ 725.00K---
Gross Profit
$ 8.87M$ 4.38M$ 8.31M$ 12.00M--
Operating Expense
$ 86.86M$ 70.88M$ 30.33M$ 42.91M$ 40.18M$ 30.08M
Operating Income
$ -77.65M$ -65.76M$ -21.30M$ -30.91M$ -40.18M$ -30.08M
Net Non Operating Interest Income Expense
$ -4.99M$ -1.22M$ -1.70M$ -4.17M$ -2.51M$ 1.88M
Other Income Expense
$ -2.58M$ -2.55M$ -1.50M---
Pretax Income
$ -81.24M$ -67.00M$ -24.49M$ -35.08M$ -42.69M$ -28.21M
Tax Provision
$ -1.55M$ -1.55M$ -955.00K$ -2.70M$ -2.94M-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -82.18M$ -67.00M$ -24.49M$ -35.08M$ -42.69M$ -28.21M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 40.20M$ 68.35M$ 30.33M$ 42.91M$ 40.18M$ 30.08M
Net Income From Continuing And Discontinued Operation
$ -84.99M$ -67.00M$ -24.49M$ -35.08M$ -42.69M$ -28.21M
Normalized Income
$ -54.23M--$ -37.78M--
Interest Expense
------
EBIT
$ -54.50M$ -63.03M$ -22.32M$ -30.79M$ -39.66M$ -28.21M
EBITDA
$ -53.47M$ -62.20M$ -21.60M$ -30.31M$ -39.43M$ -29.01M
Currency in USD

Verrica Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis